Fierce Pharma April 17, 2024
As COVID-19 moves into an endemic phase, though rates of coronavirus infections and hospitalizations continue to fall, cases of long COVID appear to be slowly ticking upward. According to data from the U.S. Centers for Disease Control and Prevention, the segment of American adults who have experienced long COVID is now hovering around 17.4%, up from a tally closer to 15% in surveys taken throughout last year.
To date, there are no FDA-approved treatments for long COVID, and researchers are still working to better understand the disease—especially since it can present with any of more than 200 symptoms—both of which are key plot points in the latest installment of Pfizer’s long-running “Dear Scientist” series.
Each entry in the content campaign,...
Today's Sponsors
Today's Sponsor